VUNO
| Market cap | ₩98.4B |
| PE ratio | – |
| Forward PE | – |
| PB ratio | 2.32 |
| EPS | −₩789 |
| Dividend (yield) | – |
| Analysts (1–5) | – |
| Price target | – |
| Volume | 805,752 |
| Trading value | ₩5.8B |
| Day’s range | ₩6,930 – ₩7,560 |
| 52-week range | ₩4,235 – ₩28,350 |
| Foreign ownership KR | 3.87% |
| Foreign net buy (Oct 23) KR | +4,762 sh |
| Book value / share | ₩2,549 |
| Founded | 2014 |
Close (KRW) Foreign ownership, % of shares (right axis)
Foreign, institutional and retail net buying KR data
Shares by trading day; positive means net buying. Korea publishes investor-type flows for every stock — global sites such as Yahoo or StockAnalysis do not show them.
| Date | Close | Foreigners | Institutions | Retail | Foreign ownership |
|---|---|---|---|---|---|
| Oct 23 | ₩5,910 | +4,762 | +2 | −4,741 | 3.98% |
| Oct 22 | ₩6,110 | −175 | +3 | +547 | 3.87% |
| Oct 21 | ₩6,260 | −6,016 | −34 | +6,093 | 3.85% |
| Oct 20 | ₩6,480 | −25,384 | −367 | +25,783 | 3.59% |
| Oct 19 | ₩6,860 | +4,056 | −470 | −4,840 | 4.14% |
Financials
Annual, consolidated where available, KRW. Columns ending in E are analyst consensus estimates. Source: company filings (DART) via Naver Finance.
| Item | FY2023 | FY2024 | FY2025 | FY2026E |
|---|---|---|---|---|
| Revenue | ₩13.3B | ₩25.9B | ₩34.8B | – |
| Operating income | −₩15.7B | −₩12.5B | −₩4.9B | – |
| Net income | −₩15.6B | −₩13.0B | −₩5.8B | – |
| Operating margin | −118.08% | −48.13% | −14.16% | – |
| Return on equity | −131.81% | −72.91% | −17.30% | – |
| Debt-to-equity | 349.38% | 63.49% | 39.53% | – |
| EPS | −₩1,181 | −₩938 | −₩413 | – |
| Dividend per share | – | – | – | – |
Peers
| Seers 458870 | ₩26,300 | −5.57% |
| Lunit 328130 | ₩14,650 | −0.27% |
| Infinitt Healthcare 071200 | ₩10,460 | −1.60% |
| Sky Labs 386380 | ₩11,010 | +3.09% |
| 3billion 394800 | ₩5,580 | −1.24% |
| GC MediAI 032620 | ₩2,870 | −1.37% |
About
VUNO is a deep-learning medical AI company that analyses medical images and biosignals to provide solutions from diagnosis to prognosis prediction. It says its VUNO Med-BoneAge was Korea's first AI medical device, and it serves hospitals, device makers and consumers with a focus on subscription services. Founded in 2014, it listed on the KOSDAQ in 2021 and is expanding in Japan, Europe, China and the US.
VUNO, Inc. is listed on the KOSDAQ market of the Korea Exchange under the ticker 338220. Industry: Software & game publishing.
VUNO in our notes
Direct KRX access through a global broker, a US-listed ADR where one exists, or a Korea ETF — compared in our guide.
Data: Korea Exchange regular-session closing prices, volume and day’s range via Daum Finance, checked against a Naver Finance snapshot at the close; investor flows, foreign ownership and ratios via Naver Finance; company information from DART (Financial Supervisory Service). Updated after each Korean market close; ratios as of Oct 23, 2026; investor flows as of Oct 23, 2026. Delayed data, not investment advice.